Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients

Background Depigmentation of the substantia nigra (SN) and locus coeruleus (LC) is a conspicuous pathological feature of Parkinson's disease (PD) and is related to the loss of neuromelanin, whose paramagnetic properties result in high signal on specific T1‐weighted magnetic resonance imaging (M...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of neurology 2015-03, Vol.22 (3), p.540-546
Hauptverfasser: Reimão, S., Pita Lobo, P., Neutel, D., Correia Guedes, L., Coelho, M., Rosa, M. M., Ferreira, J., Abreu, D., Gonçalves, N., Morgado, C., Nunes, R. G., Campos, J., Ferreira, J. J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 546
container_issue 3
container_start_page 540
container_title European journal of neurology
container_volume 22
creator Reimão, S.
Pita Lobo, P.
Neutel, D.
Correia Guedes, L.
Coelho, M.
Rosa, M. M.
Ferreira, J.
Abreu, D.
Gonçalves, N.
Morgado, C.
Nunes, R. G.
Campos, J.
Ferreira, J. J.
description Background Depigmentation of the substantia nigra (SN) and locus coeruleus (LC) is a conspicuous pathological feature of Parkinson's disease (PD) and is related to the loss of neuromelanin, whose paramagnetic properties result in high signal on specific T1‐weighted magnetic resonance imaging (MRI). Recent studies have suggested that neuromelanin decrease in the SN and LC of PD patients may emerge as a possible diagnostic biomarker. The SN neuromelanin signal in de novo and early stage PD patients was studied to assess its diagnostic accuracy. This is the first study based on a semi‐automated MRI analysis of the neuromelanin signal in de novo PD patients. Methods The inclusion criteria were untreated de novo PD and a 2–5 year disease duration; in addition, age matched healthy controls were enrolled. These were studied with a high‐resolution T1‐weighted MRI sequence at 3 T to visualize neuromelanin. The primary outcome was SN high signal area, length and neuromelanin/midbrain ratio obtained with semi‐automated methods. Results A total of 12 de novo PD patients and 10 PD patients with a 2–5 year disease duration were evaluated. The area, length of the SN T1 high signal and the SN neuromelanin/midbrain ratio were markedly decreased in the PD groups compared with age‐matched controls, with a substantial overlap between the two PD groups. Conclusions Neuromelanin‐sensitive MRI techniques can discriminate PD patients from healthy individuals with high sensitivity and specificity. Our findings are consistent with recent findings showing that PD neuromelanin changes remain stable during the course of the disease.
doi_str_mv 10.1111/ene.12613
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1655521884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1655521884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4573-c1d12e80a64c5a208a5ed3c52b66fb8d6464c8b1d3285421cab2d9b052ac86e73</originalsourceid><addsrcrecordid>eNp1kE1vEzEQhi0EoiVw4A8gSxygh209_lpzhCq0RVVBFFRuxuudRC6JN9i7QP99p6TtAQkfbMvzzCvPw9hzEPtA6wAz7oO0oB6wXdDWNaAUPKS7MtAYELDDntR6KYSQrRSP2Y40RmntxC77fj51dQx5TIHntCy041SGNa5CTpmvwzLjmCIvWIccckSe6C3lJadqjzwPvwb-KZQfKRPwqvI-VQwV-SaMCfNYn7JHi7Cq-Oz2nLGv7-dfDo-b049HJ4dvT5uoTauaCD1IdCJYHU2QwgWDvYpGdtYuOtdbTQXXQa-kM1pCDJ3s33TCyBCdxVbN2Ott7qYMPyeso1-nGnFFc-AwVQ_WGCPBOU3oy3_Qy2EqmX53Q-mWMPIzY3tbKpah1oILvyk0e7nyIPyNdk_a_V_txL64TZy6Nfb35J1nAg62wO-0wqv_J_n52fwustl2pDrin_sOMu1tq1rjL86OvAF1_u3d5w_-Ql0D9v2bAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1654752155</pqid></control><display><type>article</type><title>Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Reimão, S. ; Pita Lobo, P. ; Neutel, D. ; Correia Guedes, L. ; Coelho, M. ; Rosa, M. M. ; Ferreira, J. ; Abreu, D. ; Gonçalves, N. ; Morgado, C. ; Nunes, R. G. ; Campos, J. ; Ferreira, J. J.</creator><creatorcontrib>Reimão, S. ; Pita Lobo, P. ; Neutel, D. ; Correia Guedes, L. ; Coelho, M. ; Rosa, M. M. ; Ferreira, J. ; Abreu, D. ; Gonçalves, N. ; Morgado, C. ; Nunes, R. G. ; Campos, J. ; Ferreira, J. J.</creatorcontrib><description>Background Depigmentation of the substantia nigra (SN) and locus coeruleus (LC) is a conspicuous pathological feature of Parkinson's disease (PD) and is related to the loss of neuromelanin, whose paramagnetic properties result in high signal on specific T1‐weighted magnetic resonance imaging (MRI). Recent studies have suggested that neuromelanin decrease in the SN and LC of PD patients may emerge as a possible diagnostic biomarker. The SN neuromelanin signal in de novo and early stage PD patients was studied to assess its diagnostic accuracy. This is the first study based on a semi‐automated MRI analysis of the neuromelanin signal in de novo PD patients. Methods The inclusion criteria were untreated de novo PD and a 2–5 year disease duration; in addition, age matched healthy controls were enrolled. These were studied with a high‐resolution T1‐weighted MRI sequence at 3 T to visualize neuromelanin. The primary outcome was SN high signal area, length and neuromelanin/midbrain ratio obtained with semi‐automated methods. Results A total of 12 de novo PD patients and 10 PD patients with a 2–5 year disease duration were evaluated. The area, length of the SN T1 high signal and the SN neuromelanin/midbrain ratio were markedly decreased in the PD groups compared with age‐matched controls, with a substantial overlap between the two PD groups. Conclusions Neuromelanin‐sensitive MRI techniques can discriminate PD patients from healthy individuals with high sensitivity and specificity. Our findings are consistent with recent findings showing that PD neuromelanin changes remain stable during the course of the disease.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.12613</identifier><identifier>PMID: 25534480</identifier><identifier>CODEN: EJNEFL</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Biomarkers ; Female ; Humans ; locus coeruleus ; Locus Coeruleus - metabolism ; magnetic resonance imaging ; Magnetic Resonance Imaging - methods ; Magnetic Resonance Imaging - standards ; Male ; Melanins - metabolism ; Middle Aged ; neuromelanin ; Parkinson Disease - metabolism ; Parkinson's disease ; Sensitivity and Specificity ; substantia nigra ; Substantia Nigra - metabolism</subject><ispartof>European journal of neurology, 2015-03, Vol.22 (3), p.540-546</ispartof><rights>2014 EAN</rights><rights>2014 EAN.</rights><rights>European Journal of Neurology © 2015 European Federation of Neurological Societies</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4573-c1d12e80a64c5a208a5ed3c52b66fb8d6464c8b1d3285421cab2d9b052ac86e73</citedby><cites>FETCH-LOGICAL-c4573-c1d12e80a64c5a208a5ed3c52b66fb8d6464c8b1d3285421cab2d9b052ac86e73</cites><orcidid>0000-0002-4008-8110</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fene.12613$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fene.12613$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25534480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reimão, S.</creatorcontrib><creatorcontrib>Pita Lobo, P.</creatorcontrib><creatorcontrib>Neutel, D.</creatorcontrib><creatorcontrib>Correia Guedes, L.</creatorcontrib><creatorcontrib>Coelho, M.</creatorcontrib><creatorcontrib>Rosa, M. M.</creatorcontrib><creatorcontrib>Ferreira, J.</creatorcontrib><creatorcontrib>Abreu, D.</creatorcontrib><creatorcontrib>Gonçalves, N.</creatorcontrib><creatorcontrib>Morgado, C.</creatorcontrib><creatorcontrib>Nunes, R. G.</creatorcontrib><creatorcontrib>Campos, J.</creatorcontrib><creatorcontrib>Ferreira, J. J.</creatorcontrib><title>Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background Depigmentation of the substantia nigra (SN) and locus coeruleus (LC) is a conspicuous pathological feature of Parkinson's disease (PD) and is related to the loss of neuromelanin, whose paramagnetic properties result in high signal on specific T1‐weighted magnetic resonance imaging (MRI). Recent studies have suggested that neuromelanin decrease in the SN and LC of PD patients may emerge as a possible diagnostic biomarker. The SN neuromelanin signal in de novo and early stage PD patients was studied to assess its diagnostic accuracy. This is the first study based on a semi‐automated MRI analysis of the neuromelanin signal in de novo PD patients. Methods The inclusion criteria were untreated de novo PD and a 2–5 year disease duration; in addition, age matched healthy controls were enrolled. These were studied with a high‐resolution T1‐weighted MRI sequence at 3 T to visualize neuromelanin. The primary outcome was SN high signal area, length and neuromelanin/midbrain ratio obtained with semi‐automated methods. Results A total of 12 de novo PD patients and 10 PD patients with a 2–5 year disease duration were evaluated. The area, length of the SN T1 high signal and the SN neuromelanin/midbrain ratio were markedly decreased in the PD groups compared with age‐matched controls, with a substantial overlap between the two PD groups. Conclusions Neuromelanin‐sensitive MRI techniques can discriminate PD patients from healthy individuals with high sensitivity and specificity. Our findings are consistent with recent findings showing that PD neuromelanin changes remain stable during the course of the disease.</description><subject>Aged</subject><subject>Biomarkers</subject><subject>Female</subject><subject>Humans</subject><subject>locus coeruleus</subject><subject>Locus Coeruleus - metabolism</subject><subject>magnetic resonance imaging</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Magnetic Resonance Imaging - standards</subject><subject>Male</subject><subject>Melanins - metabolism</subject><subject>Middle Aged</subject><subject>neuromelanin</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson's disease</subject><subject>Sensitivity and Specificity</subject><subject>substantia nigra</subject><subject>Substantia Nigra - metabolism</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1vEzEQhi0EoiVw4A8gSxygh209_lpzhCq0RVVBFFRuxuudRC6JN9i7QP99p6TtAQkfbMvzzCvPw9hzEPtA6wAz7oO0oB6wXdDWNaAUPKS7MtAYELDDntR6KYSQrRSP2Y40RmntxC77fj51dQx5TIHntCy041SGNa5CTpmvwzLjmCIvWIccckSe6C3lJadqjzwPvwb-KZQfKRPwqvI-VQwV-SaMCfNYn7JHi7Cq-Oz2nLGv7-dfDo-b049HJ4dvT5uoTauaCD1IdCJYHU2QwgWDvYpGdtYuOtdbTQXXQa-kM1pCDJ3s33TCyBCdxVbN2Ott7qYMPyeso1-nGnFFc-AwVQ_WGCPBOU3oy3_Qy2EqmX53Q-mWMPIzY3tbKpah1oILvyk0e7nyIPyNdk_a_V_txL64TZy6Nfb35J1nAg62wO-0wqv_J_n52fwustl2pDrin_sOMu1tq1rjL86OvAF1_u3d5w_-Ql0D9v2bAA</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Reimão, S.</creator><creator>Pita Lobo, P.</creator><creator>Neutel, D.</creator><creator>Correia Guedes, L.</creator><creator>Coelho, M.</creator><creator>Rosa, M. M.</creator><creator>Ferreira, J.</creator><creator>Abreu, D.</creator><creator>Gonçalves, N.</creator><creator>Morgado, C.</creator><creator>Nunes, R. G.</creator><creator>Campos, J.</creator><creator>Ferreira, J. J.</creator><general>Blackwell Publishing Ltd</general><general>John Wiley &amp; Sons, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4008-8110</orcidid></search><sort><creationdate>201503</creationdate><title>Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients</title><author>Reimão, S. ; Pita Lobo, P. ; Neutel, D. ; Correia Guedes, L. ; Coelho, M. ; Rosa, M. M. ; Ferreira, J. ; Abreu, D. ; Gonçalves, N. ; Morgado, C. ; Nunes, R. G. ; Campos, J. ; Ferreira, J. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4573-c1d12e80a64c5a208a5ed3c52b66fb8d6464c8b1d3285421cab2d9b052ac86e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Biomarkers</topic><topic>Female</topic><topic>Humans</topic><topic>locus coeruleus</topic><topic>Locus Coeruleus - metabolism</topic><topic>magnetic resonance imaging</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Magnetic Resonance Imaging - standards</topic><topic>Male</topic><topic>Melanins - metabolism</topic><topic>Middle Aged</topic><topic>neuromelanin</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson's disease</topic><topic>Sensitivity and Specificity</topic><topic>substantia nigra</topic><topic>Substantia Nigra - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reimão, S.</creatorcontrib><creatorcontrib>Pita Lobo, P.</creatorcontrib><creatorcontrib>Neutel, D.</creatorcontrib><creatorcontrib>Correia Guedes, L.</creatorcontrib><creatorcontrib>Coelho, M.</creatorcontrib><creatorcontrib>Rosa, M. M.</creatorcontrib><creatorcontrib>Ferreira, J.</creatorcontrib><creatorcontrib>Abreu, D.</creatorcontrib><creatorcontrib>Gonçalves, N.</creatorcontrib><creatorcontrib>Morgado, C.</creatorcontrib><creatorcontrib>Nunes, R. G.</creatorcontrib><creatorcontrib>Campos, J.</creatorcontrib><creatorcontrib>Ferreira, J. J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reimão, S.</au><au>Pita Lobo, P.</au><au>Neutel, D.</au><au>Correia Guedes, L.</au><au>Coelho, M.</au><au>Rosa, M. M.</au><au>Ferreira, J.</au><au>Abreu, D.</au><au>Gonçalves, N.</au><au>Morgado, C.</au><au>Nunes, R. G.</au><au>Campos, J.</au><au>Ferreira, J. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2015-03</date><risdate>2015</risdate><volume>22</volume><issue>3</issue><spage>540</spage><epage>546</epage><pages>540-546</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><coden>EJNEFL</coden><abstract>Background Depigmentation of the substantia nigra (SN) and locus coeruleus (LC) is a conspicuous pathological feature of Parkinson's disease (PD) and is related to the loss of neuromelanin, whose paramagnetic properties result in high signal on specific T1‐weighted magnetic resonance imaging (MRI). Recent studies have suggested that neuromelanin decrease in the SN and LC of PD patients may emerge as a possible diagnostic biomarker. The SN neuromelanin signal in de novo and early stage PD patients was studied to assess its diagnostic accuracy. This is the first study based on a semi‐automated MRI analysis of the neuromelanin signal in de novo PD patients. Methods The inclusion criteria were untreated de novo PD and a 2–5 year disease duration; in addition, age matched healthy controls were enrolled. These were studied with a high‐resolution T1‐weighted MRI sequence at 3 T to visualize neuromelanin. The primary outcome was SN high signal area, length and neuromelanin/midbrain ratio obtained with semi‐automated methods. Results A total of 12 de novo PD patients and 10 PD patients with a 2–5 year disease duration were evaluated. The area, length of the SN T1 high signal and the SN neuromelanin/midbrain ratio were markedly decreased in the PD groups compared with age‐matched controls, with a substantial overlap between the two PD groups. Conclusions Neuromelanin‐sensitive MRI techniques can discriminate PD patients from healthy individuals with high sensitivity and specificity. Our findings are consistent with recent findings showing that PD neuromelanin changes remain stable during the course of the disease.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25534480</pmid><doi>10.1111/ene.12613</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4008-8110</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1351-5101
ispartof European journal of neurology, 2015-03, Vol.22 (3), p.540-546
issn 1351-5101
1468-1331
language eng
recordid cdi_proquest_miscellaneous_1655521884
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Aged
Biomarkers
Female
Humans
locus coeruleus
Locus Coeruleus - metabolism
magnetic resonance imaging
Magnetic Resonance Imaging - methods
Magnetic Resonance Imaging - standards
Male
Melanins - metabolism
Middle Aged
neuromelanin
Parkinson Disease - metabolism
Parkinson's disease
Sensitivity and Specificity
substantia nigra
Substantia Nigra - metabolism
title Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T11%3A14%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Substantia%20nigra%20neuromelanin%20magnetic%20resonance%20imaging%20in%20de%20novo%20Parkinson's%20disease%20patients&rft.jtitle=European%20journal%20of%20neurology&rft.au=Reim%C3%A3o,%20S.&rft.date=2015-03&rft.volume=22&rft.issue=3&rft.spage=540&rft.epage=546&rft.pages=540-546&rft.issn=1351-5101&rft.eissn=1468-1331&rft.coden=EJNEFL&rft_id=info:doi/10.1111/ene.12613&rft_dat=%3Cproquest_cross%3E1655521884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1654752155&rft_id=info:pmid/25534480&rfr_iscdi=true